A Long-Term Follow-up Study of the Severe Parkinson’s Disease Patients Administered the IPS101A Gene Therapy Product.

by | Jun 5, 2026 | Clinical Trials | 0 comments

​ Conditions: Parkinson Disease; Parkinson’s Disease

Sponsors: Innopeutics Corporation

Not yet recruiting Conditions: Parkinson Disease; Parkinson’s Disease
Sponsors: Innopeutics Corporation
Not yet recruiting 

Submit a Comment

Your email address will not be published. Required fields are marked *